Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 18/20 | 0.73 |
| ▸ | KDR | P35968 | 8/20 | 0.73 |
| ▸ | JAK3 | P52333 | 2/20 | 0.73 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.73 |
| ▸ | SRC | P12931 | 16/20 | 0.60 |
| ▸ | KIT | P10721 | 16/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494660 | 0.93 | LCK (0.64) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL5491730 | 0.86 | LCK (0.55) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL5494575 | 0.84 | LCK (1.00) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL17803857 | 0.83 | LCK (0.62) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL5489026 | 0.82 | LCK (0.55) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL5496119 | 0.82 | LCK (0.66) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL21416857 | 0.80 | LCK (0.49) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL5504290 | 0.79 | LCK (0.70) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL5488838 | 0.79 | MAP4K4 (0.61) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL1345861 | 0.79 | LCK (0.55) | LCKKDRJAK3MAPK14SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | claimed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | claimed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | claimed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | claimed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | disclosed |
| EP-2585439-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2013-05-01 | — | — | EP | disclosed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
| WO-2011161159-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2011-12-29 | — | — | WO | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | CAMK2D, CAMK2A, CAMK2B | LCK 244/4885KDR 969/4885JAK3 824/4885 |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | LCK 392/4885KDR 296/4885JAK3 258/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | LCK 106/4885KDR 1044/4885JAK3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.